Details of Host Protein-DME Interaction (HOSPPI)

General Information of Drug-Metabolizing Enzyme (DME ID: DME1055)
DME Name Cytidine deaminase (cdd), Escherichia coli DME Info
UniProt ID
CDD_ECOLI
EC Number    EC: 3.5.4.5     (Click to Show/Hide the Complete EC Tree)
Hydrolases
Carbon-nitrogen hydrolase
Cyclic amidine hydrolase
EC: 3.5.4.5
Lineage    Species: Escherichia coli     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus: Escherichia
Species: Escherichia coli
Subspecies: Escherichia coli K-12
Interactome
Disease Specific Interactions between Host Protein and DME (HOSPPI)
      Drug co-metabolism
               Cometabolized drug: Gemcitabine Click to Show/Hide the Full List of HOSPPI:        2 HOSPPI
                            Cytidine aminohydrolase (CDA) Click to Show/Hide the Cometabolization Info
DME ID DME0080 DME Info
Uniprot ID
CDD_HUMAN
Interaction Name CDA-cdd interaction [1], [2]
Description The interaction, between human Cytidine aminohydrolase and Cytidine deaminase from Escherichia coli which collectively metabolize the drug Gemcitabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
                            Uridine/cytidine monophosphate kinase (UMPK) Click to Show/Hide the Cometabolization Info
DME ID DME0456 DME Info
Uniprot ID
KCY_HUMAN
Interaction Name UMPK-cdd interaction [1], [3]
Description The interaction, between human Uridine/cytidine monophosphate kinase and Cytidine deaminase from Escherichia coli which collectively metabolize the drug Gemcitabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
References
1 Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
2 Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.
3 Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos. 2008 Sep;36(9):1951-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.